ELV

Elevance Health, Inc. 10-Q Summary: Q3 2025

Business Context and Reporting Period

This summary covers Elevance Health, Inc.'s (ELV) unaudited financial results for the quarterly period ended September 30, 2025. Elevance is a leading U.S. health insurer serving approximately 45.4 million medical members as of the reporting date. The company operates through four reportable segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The reporting period reflects the impact of recent acquisitions, including Centers Plan for Healthy Living and CareBridge, completed in late 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Operating revenue increased 12.0% in Q3 and 13.9% YTD compared to 2024, driven by premium rate increases, growth in Medicare Advantage membership, and recent acquisitions. This was partially offset by Medicaid membership attrition due to eligibility redeterminations.
• Profitability: Q3 Net Income rose 17.8% year-over-year, aided by reduced losses on financial instruments and a lower effective tax rate (15.6% vs. 26.6%). However, YTD Net Income declined 8.0% due to lower operating gains in the Health Benefits segment and higher net losses on financial instruments.
• Medical Cost Trends: The benefit expense ratio increased to 91.3% in Q3 (up 180 basis points) and 88.9% YTD (up 170 basis points). This reflects elevated medical cost trends in Medicare, Medicaid, and Affordable Care Act (ACA) plans.
• Membership: Total medical membership declined 0.9% to 45.4 million. Decreases in BlueCard and Medicaid memberships were partially offset by a 9.7% increase in Medicare Advantage members.
• Debt Activity: In September 2025, the company issued $3.0 billion in new senior notes (maturing 2028, 2032, 2036, and 2055) to refinance maturing debt and fund general corporate purposes. The debt-to-capital ratio stands at 42.1%.

Guidance, Outlook, and Risks

• Regulatory Environment: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 introduces changes to Medicaid eligibility, work requirements, and provider taxes, with most provisions effective in 2027-2028. The company is monitoring the expiration of enhanced Premium Tax Credits at the end of 2025.
• Star Ratings: Approximately 55% of Medicare Advantage members are enrolled in plans rated 4.0 Stars or higher based on 2026 ratings released in October 2025, which will impact 2027 bonus payments.
• Litigation: The company paid a $666 million settlement related to the Blue Cross Blue Shield Antitrust Litigation (Provider Settlement Agreement) in September 2025. Follow-on cases from entities that opted out of the settlement remain pending.
• Capital Allocation: The company continues its share repurchase program, having repurchased $2.134 billion of stock YTD 2025. A quarterly dividend of $1.71 per share was declared for Q4 2025.
• Investment Portfolio: Net losses on financial instruments were $125 million in Q3 and $371 million YTD, primarily driven by unrealized losses on equity securities and impairments on other invested assets, though these losses decreased compared to the prior year.

Investor Verification Checklist

• Medical Cost Trend Sustainability: Verify if the elevated benefit expense ratio (91.3% in Q3) is a temporary anomaly or a structural shift requiring further rate adjustments.
• Medicaid Redetermination Impact: Assess the long-term trajectory of Medicaid membership attrition and the potential for increased morbidity in the remaining population.
• Regulatory Exposure: Review the specific financial implications of the OBBBA and the potential expiration of ACA Premium Tax Credits in late 2025.
• Investment Volatility: Monitor the "Net losses on financial instruments" line item, as unrealized losses on equity and alternative investments continue to impact net income.
• Acquisition Integration: Evaluate the contribution of recent acquisitions (Centers, CareBridge) to the Carelon Services segment's operating gain growth.